Development of an Influenza/COVID-19 Combination mRNA Vaccine Containing a Novel Multivalent Antigen Design That Enhances Immunogenicity of Influenza Virus B Hemagglutinins
Our data demonstrate that the multimerization of antigens expressed as complex fusion proteins is a powerful antigen design approach that may be broadly applied toward mRNA vaccine development.
Authors
- Zhijun Guo
- Evan Kurt (ORCID: https://orcid.org/0000-0002-5402-373X)
- Kimberlin Leigh
- Marcin Bugno
- Feng Yan (ORCID: https://orcid.org/0000-0001-8957-1851)
- Ying Liu (ORCID: https://orcid.org/0000-0003-1699-9309)
- Jianbo Zhu (ORCID: https://orcid.org/0000-0001-7262-0936)
- Elena Thornhill-Wadolowski
- Jaewoo Lee (ORCID: https://orcid.org/0000-0003-3760-1806)
- Zihao Wang (ORCID: https://orcid.org/0000-0002-6994-2309)
- Dana L. Ruter
- Mayur Gajera
- Labannya Samanta
Institutions
- Shanghai CASB Biotechnology (China) (CN)
- Hangzhou DAC Biotech (China) (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2025-06-11
- DOI
- https://doi.org/10.3390/vaccines13060628
- Citations
- 6
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.13